Literature DB >> 2437696

Apparent lack of neutralizing antibodies in Aleutian disease is due to masking of antigenic sites by phospholipids.

B Stolze, O R Kaaden.   

Abstract

It is generally accepted that Aleutian disease virus (ADV) cannot be neutralized by antibodies either in vivo or in vitro. We found several ways to demonstrate neutralization of ADV by specific antibodies from mink. It was essential to make ADV monodisperse by treatment with sodium lauroyl sarkosyl or n-butanol or by filtration through 0.05-micron membranes before neutralization tests. In kinetic experiments, there was a 95% loss of virus infectivity within the first 5 min of reaction, but a resistant fraction of about 1% remained after 1.5 hr of incubation. Neutralization titers between 1:160 and 1:640 were found in sera from naturally and experimentally infected mink. A positive relation was consistently found between neutralization and ELISA titers. Furthermore, separation of phospholipids from ADV was shown by thin-layer chromatography of butanol-extracted virions. By reconstitution of monodispersed ADV with various lipids, phospholipids were found to interfere with virus neutralization by attachment to the virus surface.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2437696     DOI: 10.1016/0042-6822(87)90251-0

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  6 in total

1.  Aleutian disease parvovirus infection of mink and ferrets elicits an antibody response to a second nonstructural viral protein.

Authors:  D D Porter; H G Porter; A E Larsen
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

2.  Passive transfer of antiviral antibodies restricts replication of Aleutian mink disease parvovirus in vivo.

Authors:  S Alexandersen; S Larsen; A Cohn; A Uttenthal; R E Race; B Aasted; M Hansen; M E Bloom
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

3.  Expression of Aleutian mink disease parvovirus capsid proteins in defined segments: localization of immunoreactive sites and neutralizing epitopes to specific regions.

Authors:  M E Bloom; D A Martin; K L Oie; M E Huhtanen; F Costello; J B Wolfinbarger; S F Hayes; M Agbandje-McKenna
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

4.  Identification of aleutian mink disease parvovirus capsid sequences mediating antibody-dependent enhancement of infection, virus neutralization, and immune complex formation.

Authors:  M E Bloom; S M Best; S F Hayes; R D Wells; J B Wolfinbarger; R McKenna; M Agbandje-McKenna
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

5.  Aleutian mink disease parvovirus infection of mink macrophages and human macrophage cell line U937: demonstration of antibody-dependent enhancement of infection.

Authors:  H Kanno; J B Wolfinbarger; M E Bloom
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  Expression of Aleutian mink disease parvovirus capsid proteins by a recombinant vaccinia virus: self-assembly of capsid proteins into particles.

Authors:  D L Clemens; J B Wolfinbarger; S Mori; B D Berry; S F Hayes; M E Bloom
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.